Ibuprofen-β-cyclodextrin Inclusion Complex: Preparation, Characterization, Physico-Chemical Properties and In vitro Dissolution Behavior

Abstract

Abstract: Inclusion complexation between ibuprofen (IBF) and β cyclodextrin (β-CD) was investigated. Phase solubility studies of the complexation suggested the formation of a 1:3 complex and a 2:3 complex between IBF and β-CD at room temperature (23 ºC) and at 37 ºC respectively. Solid inclusion complexes were prepared by the homogeneous coprecipitation method. Scanning electron microscopy, differential scanning calorimetry, IR spectroscopy, and Xray diffractometry were used for the characterization and evaluation of the complexes. The solubility and dissolution rate of the complexes formed were found to have improved considerably over that of the physical mixture and the drug alone, indicating that β-cyclodextrin played an important role in the solubilization of ibuprofen.

Key words: Ibuprofen, β-Cyclodextrin, Inclusion complexation, Solubility, In vitro dissolution rate

Supporting:

Gul Majid Khan, Jia-Bi Zhu . Ibuprofen-β-cyclodextrin Inclusion Complex: Preparation, Characterization, Physico-Chemical Properties and In vitro Dissolution Behavior[J]. .

References

[1] Martin A, Swarbrick J, Cammarata A. Physical Pharmacy, 3rd ed., Lea & Febiger, Philadelphia, 1983: 272.
[2] Repta AJ, Shafter E. In : Yalkovsky SH, ed. Techniques of Solubilization of Drugs, Dekkar, New York, 1981: 135, 159.
[3] Lofts T, Guomundsdottir TK, Frioriksdottir H. Drug Dev Ind Pharm, 1996, 22: 401.
[4] Szejtli J. In: Samolen VF, Ball L, Willey A. eds. Cont rolled Drug Bioavailability . Vol. 3, Inter Science Publications, 1985: 365.
[5] Sanghavi NM, Choudri KB, Matharu RS, et al. Drug Dev Ind Pharm, 1993, 19: 701.
[6] Labendera JT, Lopez ME, Penin LS, et al. J Pharm Biopharm, 1993, 39: 225.
[7] Pitha J, Szente L, Szejtli J. Molecular Encapsulation of Drugs by CDs and Congeners. In: Bruck SD, Controlled Drug Delivery, Vol. 1. Basic Concepts. CRC Press Inc, Boca Raton, 1983: 125.
[8] Jones SP, Grand DW, Parr GD. Acta Pharm Tecnol, 1984, 30: 213.
[9] Loftsson T, Olafsdottir BJ. Int J Pharm, 1985, 66: 289.
[10] Puglisi G, Santagati NA, Ventura CA, et al. J Pharm Pharmacol, 1991, 43: 430.
[11] Duchene D, Glomot F, Vaution C. In: Duchene D and Desante, eds. Cyclodext rins and Their Industrial Uses. Paris, 1987: 6.
[12] Duchene D, Vaution C, Glomot F. Amelioration de la Dissolution et de la Biodisponibilitides Principles Actifs par Inclusion dans les CDs, S TP Pharma, 19852b : 1, 323.
[13] Duchene D, Debrueres B, Vaution C. Improvement of Drug Stability by Cyclodextrin Inclusion Complexation, STP Pharma, 19852a : 1, 37.
[14] Higuchi T, Conners KA. Phase Solubility Techniques. A dv A nal Chem Inst r, 1965 : 4, 117.
[15] Nagarsenkar MS, Shenai H. Drug Dev Ind Pharm, 1996, 22 : 987.
[16] Nakai Y. Drug Dev Ind Pharm, 1986, 12 : 1017.
[17] Szejtli J . Cyclodext rins and Thei r I nclusion Complexes . Akademia Kiado, Budapest, 1982 : 95.
[18] Green AR, Miller ES, Guillory J K. J Pharm Sci, 1991, 80 : 186.
[19] Najeeb N, Suleiman M. Drug Dev Ind Pharm, 1985, 11 : 2169.
[20] Hassegawa A, Kawamura R, Nakagawa H, et al. Chem Pharm B ull, 1986, 34 : 2183.
[21] Martin A, Swarbrick J, Cammarata A. Physical Pharmacy 3rd ed., Lea & Febiger. Philadelphia, 1983: 513.
[22] Sekikawa H, Nakano M, Arita T. Chem Pharm B ull, 1978, 26: 118.
[23] Kislalioglu MS, Khan MA, Blont C. J Pharm Sci, 1991, 80: 799.
[24] Vromans H, Eissons AC, Coenraad FL. Drug Dev Ind Pharm, 1989, 35: 250.